RedHill Biopharma Ltd. (RDHL) intrinsic value & 10-year financials
RedHill Biopharma Ltd. (RDHL) has a Graham intrinsic value of $0.07 per share. Over the last 10 fiscal years revenue grew 140.4% a year to $8.0M, with an average return on invested capital of -3.8%.
- Graham intrinsic value
- $0.07
- Revenue (FY2024)
- $8.0M
- Revenue growth (10-yr CAGR)
- 140.4%
- ROIC (10-yr avg)
- -3.8%
- Free cash flow (FY2024)
- -$9.4M
RDHL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2024 | $8.0M | -$8.3M | $0.00 | -$9.4M | -181.7% | 632.6% |
| FY2023 | $6.5M | $23.9M | $0.00 | -$35.8M | 193.4% | 51.1% |
| FY2022 | $61.8M | -$71.7M | -$0.01 | -$29.4M | -69.3% | -130.5% |
| FY2021 | $85.8M | -$97.7M | -$0.01 | -$65.2M | -94.6% | -151.6% |
| FY2020 | $64.4M | -$76.2M | -$0.01 | -$49.0M | -99.0% | -115.5% |
| FY2019 | $6.3M | -$42.3M | -$0.01 | -$40.9M | -686.7% | -76.1% |
| FY2018 | $8.4M | -$38.8M | -$0.01 | -$34.5M | -470.5% | -80.7% |
| FY2017 | $4.0M | -$45.5M | -$0.01 | -$44.9M | -1297.0% | -84.5% |
| FY2016 | $101.0K | -$29.4M | -$0.01 | -$28.3M | -30240.6% | -47.8% |
| FY2015 | $3.0K | -$21.1M | -$0.01 | -$17.8M | -733400.0% | -35.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
RedHill Biopharma Ltd. is a consistent compounder, expanding top-line revenue at 140.4% annually over the past decade.
RedHill Biopharma Ltd. has historically struggled to out-earn its cost of capital, averaging just -49.1% ROIC.
RedHill Biopharma Ltd. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, RedHill Biopharma Ltd. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.07 per share.